Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced an oral presentation of data related to studies conducted to better understand the relationship between CD44, EGFR and p16 expression in oral cavity and oropharyngeal cancers, and whether particular patterns of CD44, EGFR and p16 staining are associated with overall and progression-free survival.
The studies, along with others, helped provide direction for the clinical development of Vigilant Biosciences OncAlert™ Oral Cancer and OncAlert Labs product lines as well as pipeline programs under development.
The study, titled, “Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer,” was conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and demonstrated the ability to identify the presence of the tumor-initiating and stem cell associated biomarker CD44, together with total protein, to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms.
The data will be presented in a podium presentation at the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) Foundation 2016 Annual Meeting & OTO EXPO, which will be held September 18-21, 2016 in San Diego, CA. Vigilant Biosciences will also be showcasing its OncAlert Oral Cancer and OncAlert Labs product lines at the EXPO in Booth #2343.
Details for the oral presentation are as follows:
Title: Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cancer
Presenter: Erin R Cohen, M.D.
Date: Monday, September 19, 2016
Time: 8:45 AM
Location: SDCC, Room 31A
The full schedule of events can be viewed at www.entannualmeeting.org.
In its 120th year, the AAO-HNSF Annual Meeting & OTO EXPO showcases the latest advances in the otolaryngologist-head and neck surgery, including new research findings, approaches, and treatment options. The annual meeting and expo draws more than 5,500 otolaryngology, medical experts, and professionals from around the world.
About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.
About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark™ Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.
For more information or to set up a meeting with Vigilant Biosciences at AAO-HNS, please contact Jennifer Moritz at email@example.com.